Landscape Capital Management L.L.C. Decreases Stock Position in Pfizer Inc. (NYSE:PFE)

Landscape Capital Management L.L.C. decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 35.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 29,608 shares of the biopharmaceutical company’s stock after selling 15,975 shares during the period. Landscape Capital Management L.L.C.’s holdings in Pfizer were worth $786,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. United Bank boosted its holdings in Pfizer by 3.7% in the third quarter. United Bank now owns 35,599 shares of the biopharmaceutical company’s stock valued at $1,030,000 after purchasing an additional 1,277 shares during the last quarter. Janus Henderson Group PLC raised its position in shares of Pfizer by 0.5% in the 3rd quarter. Janus Henderson Group PLC now owns 530,429 shares of the biopharmaceutical company’s stock valued at $15,348,000 after purchasing an additional 2,600 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its stake in shares of Pfizer by 35.4% during the 3rd quarter. Kovitz Investment Group Partners LLC now owns 366,690 shares of the biopharmaceutical company’s stock valued at $10,612,000 after buying an additional 95,896 shares during the last quarter. Hendershot Investments Inc. increased its stake in shares of Pfizer by 12.7% in the third quarter. Hendershot Investments Inc. now owns 24,895 shares of the biopharmaceutical company’s stock worth $720,000 after buying an additional 2,798 shares during the last quarter. Finally, DF Dent & Co. Inc. raised its holdings in Pfizer by 11.9% in the third quarter. DF Dent & Co. Inc. now owns 45,708 shares of the biopharmaceutical company’s stock valued at $1,323,000 after acquiring an additional 4,852 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Down 5.4 %

PFE opened at $22.99 on Friday. The stock’s 50 day moving average price is $25.87 and its 200 day moving average price is $26.74. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The stock has a market cap of $130.39 billion, a P/E ratio of 16.31, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a 12 month low of $22.95 and a 12 month high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s revenue was up 24.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.10 earnings per share. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on PFE shares. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Guggenheim reaffirmed a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. Bank of America reissued a “neutral” rating and set a $29.00 price target on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Insider Transactions at Pfizer

In other news, Director Ronald E. Blaylock bought 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the acquisition, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.06% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.